Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin J Pain ; 31(3): 214-21, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25654429

RESUMEN

OBJECTIVE: A survey of breakthrough pain (BTP) was performed in five palliative care units (PCU), seven oncology departments (ONC), and nine pain clinics (OPC). METHODS: A standard algorithm was used to confirm the diagnosis of BTP of patients refereed to different settings. RESULTS: 1,412 evaluable cancer patients were enrolled. 53.9% were males and the mean age was 63.7±13.1 years. The mean intensity of background pain was 2.8±0.73. Patients reported 2.4±1.1 BTP episodes/day with a mean intensity of 7.37±1.28. 80.6% patients reported that the BTP had a significant negative impact in everyday life. The majority of patients reported a fast onset of BTP, which was predictable in 50.7% of cases, while BTP with a gradual onset (>10 min) was less predictable (29%) (P=0.001). PCU patients were older, had lower Karnofsky levels, a lower number of BTP episodes/day, a slow onset of BTP onset, and a less predictable BTP. Cancer diagnosis was performed a mean of 23.5 months (SD±32.8) before the assessment. The mean duration of background pain was 3.5 months (SD±3.5), and the mean duration of any analgesic treatment was 2.5 months (SD±3). BTP started a mean of 2.2 months (SD±1.9) before the assessment. Characteristics of BTP were influenced by the course of disease, as well as the duration of background pain and initiation of BTP. Most patients took rapid onset opioids and were satisfied with the treatment. BTP diagnosis was prevalently made by ONC and OPC physicians, and rarely by GPs. CONCLUSION: This survey performed by an Italian observatory expert review group, has confirmed that the BTP represents a clinically relevant condition with a negative impact on the patient's quality of life. BTP was detected in all settings involved. A number of factors are associated with the BTP. Also factors regarding the course of disease and setting of care have been assessed. This information may help in stratifying patients or predicting the risk of development of BTP with specific characteristics.


Asunto(s)
Dolor Irruptivo/epidemiología , Dolor Irruptivo/etiología , Neoplasias/complicaciones , Dimensión del Dolor , Anciano , Dolor Irruptivo/terapia , Femenino , Encuestas Epidemiológicas , Humanos , Italia , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Clínicas de Dolor/estadística & datos numéricos , Cuidados Paliativos/estadística & datos numéricos , Valor Predictivo de las Pruebas , Calidad de Vida , Factores de Tiempo
2.
Adv Ther ; 29(5): 464-72, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22622488

RESUMEN

INTRODUCTION: Despite breakthrough pain (BTP) being one of the most severe forms of pain, there are no definitive data on its prevalence. METHODS: The authors performed a retrospective survey of the prevalence of BTP in consecutive patients in four Italian pain clinics, subsequent to application of an Italian law mandating detailed clinical records on pain characteristics, treatment, and results. Mean pain intensity was assessed with a numerical rating scale from 0 to 10. RESULTS: The authors analyzed records of 1,401 patients (58% women, 33.1% patients with cancer). Transient episodes of severe pain or BTP were referred by 790 patients (56.4%), including 58.2% of the men (342 of 588) and 55.1% of the women (448 of 813). Among the 464 patients with cancer, 70.3% reported daily exacerbation of pain. The mean BTP intensity was 8.31 ± 1.58 and 31.1% of patients reported experiencing three episodes per day. CONCLUSION: Despite some limitations of the study, the authors show that transient episodes of severe pain or BTP are significantly present both in cancer and other diseases, and that many patients are not yet receiving appropriate opioid therapy. The authors need validated tools at international level for the diagnosis and treatment of BTP in patients with cancer and for transitory and patients with severe non-cancer pain. A survey at national level is needed to estimate the prevalence of BTP in different settings, to plan specific medical education.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Dolor Irruptivo/tratamiento farmacológico , Dolor Irruptivo/epidemiología , Clínicas de Dolor/estadística & datos numéricos , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Dolor Irruptivo/diagnóstico , Vías de Administración de Medicamentos , Esquema de Medicación , Femenino , Humanos , Italia/epidemiología , Masculino , Neoplasias/complicaciones , Dolor/etiología , Dimensión del Dolor , Prevalencia , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...